New drug combo aims to boost immune attack on tough liver cancers
NCT ID NCT03655002
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This early-phase trial tested a combination of two drugs (IRX-2 and nivolumab) plus a low dose of chemotherapy in 8 adults with advanced liver cancer that had returned or spread. The goal was to find the best dose and check for side effects. The approach aims to help the immune system fight the cancer more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Texas Oncology at Baylor Charles A Sammons Cancer Center
Dallas, Texas, 75246, United States
Conditions
Explore the condition pages connected to this study.